drugset / Trial / NCT00681876
Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer
Phase 2
Terminated
16 enrolled
Hellenic Oncology Research Group
University Hospital of Crete · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase II study will evaluate the efficacy of the combination of two monoclonal antibodies (Avastin + Erbitux) with irinotecan, in patients with colorectal cancer progressed after 1st line treatment with FOLFIRI Avastin or XELIRI Avastin.
Timeline
- Start
- 2008-04
- Primary completion
- 2010-02
- Completion
- 2010-02
Outcome
Outcome not reported
Stopped (Enrollment): “Due to poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |